CLAIMS

1. A crystalline form of (10*R*)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2*H*-8,4-(metheno)pyrazolo[4,3-*h*][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile (lorlatinib) free base hydrate, having a powder X-ray diffraction (PXRD) pattern comprising peaks at 2θ values of: 8.8, 17.6 and 18.8 °2θ ± 0.2 °2θ.

2. The crystalline form of claim 1, having a PXRD pattern further comprising a peak at the 2θ value of: 9.7 °2θ ± 0.2 °2θ.

3. The crystalline form of claim 1 or 2, having a PXRD pattern further comprising a peak at the 2θ value of: 10.9 °2θ ± 0.2 °2θ.

4. The crystalline form of claim 1, 2 or 3, having a ^{13}C solid state NMR spectrum comprising resonance (ppm) values of: 40.2, 41.2 and 136.2 ppm ± 0.2 ppm.

5. The crystalline form of claim 4, having a ^{13}C solid state NMR spectrum further comprising the resonance (ppm) value of: 128.1 ppm ± 0.2 ppm.

6. The crystalline form of claim 4 or 5, having a ^{13}C solid state NMR spectrum further comprising the resonance (ppm) value of: 145.3 ppm ± 0.2 ppm.

7. The crystalline form of any one of claims 1 to 6, having a ^{19}F solid state NMR spectrum comprising a resonance (ppm) value of: -104.0 ppm ± 0.2 ppm.

8. A pharmaceutical composition comprising the crystalline form of lorlatinib free base hydrate according to any one of claims 1 to 7, and a pharmaceutically acceptable carrier or excipient.

9. A crystalline form of lorlatinib free base hydrate according to any one of claims 1 to 7, for use in the treatment of cancer in a mammal wherein the cancer is non-small cell lung cancer (NSCLC), neuroblastoma, 30 anaplastic large cell lymphoma (ALCL) or gastric cancer.

10. Use of a crystalline form of lorlatinib free base hydrate according to any one of claims 1 to 7 in the manufacture of a medicament for the treatment of non-small cell lung cancer (NSCLC), neuroblastoma, anaplastic large cell lymphoma (ALCL) or gastric cancer.